Applicant: Ohta, et al. Attorney's Docket No.: 16601-026001

Serial No.: 10/630,967 Filed: July 31, 2003

Page : 2 of 9

AMENDMENTS TO THE CLAIMS

Claims 1-57 are pending in this application, of which claims 27-37 are withdrawn from consideration.

Claims 1, 17-21, 38 and 45-49 are being canceled, without prejudice or disclaimer. Claims 2-5, 11, 15, 16, 22-26, 39-42, 50-53 and 55-57 are being amended.

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

- 1. (Canceled)
- (Currently amended) The method of Claim + 22, wherein the number of neural stem cells
 and/or neural stem cell progeny is increased by enhancing proliferation.
- (Currently amended) The method of Claim + 22, wherein the number of neural stem cells and/or neural stem cell progeny is increased by enhancing survival.
- 4. (Currently amended) The method of Claim † 22, wherein the number of neural stem cells and/or neural stem cell progeny is increased by increasing secondary neural stem cells obtained from a primary neural stem cell.
- (Currently amended) The method of Claim 4 22, wherein the neural stem cells are located in a subject.
- (Original) The method of Claim 5, wherein PACAP is added parenterally.
- 7. (Original) The method of Claim 5, wherein the subject is a mammal.
- 8. (Original) The method of Claim 7, wherein the subject is an adult.

Applicant: Ohta, et al. Attorney's Docket No.: 16601-026001

Serial No.: 10/630,967 Filed: July 31, 2003

Page : 3 of 9

(Original) The method of Claim 7, wherein the subject is a human.

 (Original) The method of Claim 5, wherein the subject is suffering from a neurodegenerative disease or brain injury.

- (Currently amended) The method of Claim 9 10, wherein the neurodegenerative disease is Alzheimer's Disease, Parkinson's Disease, or Huntington's Disease.
- 12. (Original) The method of Claim 5, wherein the subject is suffering from a stroke.
- (Original) The method of Claim 5, wherein the increase in neural stem cell number occurs in the subventricular zone of the subject.
- 14. (Original) The method of Claim 5, wherein the neural stem cells and/or progenitor cells which are derived from said neural stem cells are transplanted into said subject.
- 15. (Currently amended) The method of Claim 4 22, wherein the PACAP is PACAP38.
- 16. (Currently amended) The method of Claim 4 22, wherein the PACAP is PACAP27.
- 17. 21. (Canceled)
- 22. (Currently amended) A method for increasing neural stem cell and/or neural stem cell progeny number comprising: adding pituitary adenylate cyclase-activating polypeptide (PACAP) to multipotent neural stem cells in an amount effective to increase neural stem cell and/or neural stem cell progeny number, said method further comprising adding The method of Claim 17, wherein the at-least one growth factor is prolactin.

Applicant: Ohta, et al. Attorney's Docket No.: 16601-026001

Serial No. : 10/630,967 Filed : July 31, 2003 Page : 4 of 9

(Currently amended) The method of Claim 17 22, wherein the at least one growth factor
prolactin is added concurrently with PACAP.

- (Currently amended) The method of Claim 47 22, wherein the at least one growth factor prolactin is added sequentially with PACAP.
- (Currently amended) The method of Claim 24 wherein the at least one growth factor prolactin is added prior to the addition of PACAP.
- (Currently amended) The method of Claim 24 wherein the at least one-growth factor prolactin is added after the addition of PACAP.
- 27. (Withdrawn) A method of increasing the number of neural stem cells and/or neurospheres in a culture comprising adding pituitary adenylate cyclase-activating polypeptide (PACAP) to a neural stem cell culture to increase the number of neural stem cells and/or neurospheres generated from the neural stem cell culture.
- (Withdrawn) The method of Claim 27, wherein the neural stem cell culture is a primary culture.
- (Withdrawn) The method of Claim 27, wherein the neural stem cell culture is a clonal density culture.
- (Withdrawn) The method of Claim 27, further comprising adding a growth factor to the culture.
- (Withdrawn) The method of Claim 27, wherein the PACAP is PACAP38.
- (Withdrawn) The method of Claim 27, wherein the PACAP is PACAP27.

Applicant: Ohta, et al. Attorney's Docket No.: 16601-026001

Serial No.: 10/630,967 : July 31, 2003 Page

: 5 of 9

33. (Withdrawn) The method of Claim 30, wherein the growth factor is fibroblast growth factor-2 (FGF-2).

- 34. (Withdrawn) The method of Claim 33, further comprising adding heparan sulfate.
- 35. (Withdrawn) The method of Claim 30, wherein the growth factor is epidermal growth factor.
- (Withdrawn) The method of Claim 35, wherein the EGF is EGF51N or EGF51Q. 36.
- 37. (Withdrawn) The method of Claim 30, wherein the growth factor is prolactin.
- 38. (Canceled)
- 39. (Currently amended) The method of Claim 38 50, wherein differentiation of neural stem cells into neurons is enhanced.
- (Currently amended) The method of Claim 38 50, wherein the PACAP is PACAP38. 40.
- (Currently amended) The method of Claim 38 50, wherein the PACAP is PACAP27. 41.
- 42. (Currently amended) The method of Claim 38 50, wherein the subject is a mammal.
- 43. (Original) The method of Claim 42, wherein the subject is an adult.
- 44. (Original) The method of Claim 42, wherein the subject is a human.
- 45. 49. (Canceled)

Attorney's Docket No.: 16601-026001

Applicant : Ohta, et al. Serial No. : 10/630,967 Filed : July 31, 2003

Page : 6 of 9

50. (Currently amended) A method of enhancing differentiation of neural stem cells in a subject comprising administering pituitary adenylate cyclase-activating polypeptide (PACAP) to the subject in an amount sufficient to enhance differentiation of neural stem cells, said method further comprising administering The method of Claim 45, wherein the at-least one growth factor is prolactin.

- (Currently amended) The method Claim 45 50, wherein the at least one growth factor
 prolactin is administered to the subject prior to the administration of PACAP.
- 52. (Currently amended) The method Claim 45 50, wherein the at least one-growth factor prolactin is administered to the subject after the administration of PACAP.
- (Currently amended) The method of Claim 38 50, wherein the subject is suffering from a neurodegenerative disease or brain injury.
- 54. (Original) The method of Claim 53, wherein the neurodegenerative disease is Alzheimer's Disease, Parkinson's Disease, or Huntington's Disease.
- 55. (Currently amended) The method of Claim 38 50, wherein the subject is suffering from a stroke.
- 56. (Currently amended) The method of Claim 38 50, wherein the differentiation of neural stem cells occurs in the subventricular zone.
- 57. (Currently amended) The method of Claim 38 50, wherein the neural stem cells and/or progenitor cells which are derived from said neural stem cells are transplanted into said subject.